Recognition Functions of Pentameric C-Reactive Protein in Cardiovascular Disease

被引:28
|
作者
Agrawal, Alok [1 ]
Gang, Toh B. [1 ]
Rusinol, Antonio E. [1 ]
机构
[1] E Tennessee State Univ, Quillen Dishner Coll Med, Dept Biomed Sci, Johnson City, TN 37614 USA
关键词
LOW-DENSITY-LIPOPROTEIN; FOAM-CELL-FORMATION; ATHEROSCLEROTIC LESIONS; APOPTOTIC CELLS; IMMUNOHISTOCHEMICAL LOCALIZATION; INFARCT SIZE; OXIDIZED LDL; COMPLEMENT; BINDING; MACROPHAGES;
D O I
10.1155/2014/319215
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
C-reactive protein (CRP) performs two recognition functions that are relevant to cardiovascular disease. First, in its native pentameric conformation, CRP recognizes molecules and cells with exposed phosphocholine (PCh) groups, such as microbial pathogens and damaged cells. PCh-containing ligand-bound CRP activates the complement system to destroy the ligand. Thus, the PCh-binding function of CRP is defensive if it occurs on foreign pathogens because it results in the killing of the pathogen via complement activation. On the other hand, the PCh-binding function of CRP is detrimental if it occurs on injured host cells because it causes more damage to the tissue via complement activation; this is how CRP worsens acute myocardial infarction and ischemia/reperfusion injury. Second, in its nonnative pentameric conformation, CRP also recognizes atherogenic low-density lipoprotein (LDL). Recent data suggest that the LDL-binding function of CRP is beneficial because it prevents formation of macrophage foam cells, attenuates inflammatory effects of LDL, inhibits LDL oxidation, and reduces proatherogenic effects of macrophages, raising the possibility that nonnative CRP may show atheroprotective effects in experimental animals. In conclusion, temporarily inhibiting the PCh-binding function of CRP along with facilitating localized presence of nonnative pentameric CRP could be a promising approach to treat atherosclerosis and myocardial infarction. There is no need to stop the biosynthesis of CRP.
引用
收藏
页数:6
相关论文
共 50 条
  • [41] C-reactive protein and risk of cardiovascular disease: Evidence and clinical application
    Paul M. Ridker
    Shari S. Bassuk
    Peter P. Toth
    Current Atherosclerosis Reports, 2003, 5 (5) : 341 - 349
  • [42] C-Reactive Protein and Cardiovascular Disease in East Asians: A Systematic Review
    Saito, Isao
    Maruyama, Koutatsu
    Eguchi, Eri
    CLINICAL MEDICINE INSIGHTS-CARDIOLOGY, 2014, 8 : 35 - 42
  • [43] Monomeric C-Reactive Protein in Atherosclerotic Cardiovascular Disease: Advances and Perspectives
    Melnikov, Ivan
    Kozlov, Sergey
    Saburova, Olga
    Avtaeva, Yuliya
    Guria, Konstantin
    Gabbasov, Zufar
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (03)
  • [44] Comparison of C-reactive protein level for cardiovascular disease and chronic disorders
    Haheim, L. L. H. Lund
    Olsen, I. O.
    Nafstad, P. N.
    Schwarze, P. S.
    Ronningen, K. S. R. Skjold
    EUROPEAN HEART JOURNAL, 2006, 27 : 950 - 950
  • [45] C-reactive protein and cardiovascular disease: a review of risk prediction and interventions
    de Ferranti, S
    Rifai, N
    CLINICA CHIMICA ACTA, 2002, 317 (1-2) : 1 - 15
  • [46] Review: Biology and relevance of C-reactive protein in cardiovascular and renal disease
    Westhuyzen, J
    Healy, H
    ANNALS OF CLINICAL AND LABORATORY SCIENCE, 2000, 30 (02): : 133 - 143
  • [48] Hyperlipidaemia and cardiovascular disease: C-reactive protein and atherosclerosis - new dimensions
    Issa, BG
    CURRENT OPINION IN LIPIDOLOGY, 2002, 13 (01) : 101 - 103
  • [49] C-Reactive Protein and Heart Failure in Patients With Established Cardiovascular Disease
    Morze, Jakub
    Rynkiewicz, Andrzej
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 82 (20) : E191 - E192
  • [50] Prospective studies of C-reactive protein as a risk factor for cardiovascular disease
    Ridker, PM
    Haughie, P
    JOURNAL OF INVESTIGATIVE MEDICINE, 1998, 46 (08) : 391 - 395